KR20220007584A - 항-clec2d 항체 및 이의 사용 방법 - Google Patents

항-clec2d 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20220007584A
KR20220007584A KR1020217029054A KR20217029054A KR20220007584A KR 20220007584 A KR20220007584 A KR 20220007584A KR 1020217029054 A KR1020217029054 A KR 1020217029054A KR 20217029054 A KR20217029054 A KR 20217029054A KR 20220007584 A KR20220007584 A KR 20220007584A
Authority
KR
South Korea
Prior art keywords
seq
antibody
clec2d
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217029054A
Other languages
English (en)
Korean (ko)
Inventor
카비타 아이어 로드리게스
말로이 고쉬
수닛 마이티
요겐드라 만주나스 방갈로르 무니라주
사트야발란 무루게산
상가미트라 바타차르지
비벡 할란
수브라 프라카쉬 차크라바르티
아쉬비니 쿠마르 두베이
아누락 티와리
키르타나 마이소르 바수데바라오 신드
팔라비 라히리
사하나 비마 라오
프라치 *
슈루티 스리바스타바
라오 슈리샤 라메쉬
바라트 라빈드라 세노이
니키타 마르칸다
바그야수리 디케이
바이라바발라쿠마르 나타라얀
Original Assignee
주무토르 바이오로직스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주무토르 바이오로직스 인코포레이티드 filed Critical 주무토르 바이오로직스 인코포레이티드
Publication of KR20220007584A publication Critical patent/KR20220007584A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217029054A 2019-02-11 2020-02-10 항-clec2d 항체 및 이의 사용 방법 Pending KR20220007584A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201941005395 2019-02-11
IN201941005395 2019-02-11
PCT/US2020/017518 WO2020167668A1 (en) 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20220007584A true KR20220007584A (ko) 2022-01-18

Family

ID=69811875

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029054A Pending KR20220007584A (ko) 2019-02-11 2020-02-10 항-clec2d 항체 및 이의 사용 방법

Country Status (9)

Country Link
US (2) US11827710B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924385A1 (cg-RX-API-DMAC7.html)
JP (2) JP7612591B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220007584A (cg-RX-API-DMAC7.html)
AU (1) AU2020222891B2 (cg-RX-API-DMAC7.html)
CA (1) CA3129818A1 (cg-RX-API-DMAC7.html)
IL (1) IL285401A (cg-RX-API-DMAC7.html)
SG (1) SG11202108403UA (cg-RX-API-DMAC7.html)
WO (1) WO2020167668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220007584A (ko) 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법
CN115443140A (zh) * 2020-04-02 2022-12-06 苏州恒康生命科学有限公司 人ror-1抗体和抗ror-1-car-t细胞
US20230374142A1 (en) * 2020-10-05 2023-11-23 Monash University CLEC9A antibodies
CN116997561A (zh) * 2021-03-24 2023-11-03 森永乳业株式会社 肽及含有该肽作为有效成分的组合物
US20240398902A1 (en) * 2021-09-13 2024-12-05 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
WO2023233330A1 (en) * 2022-05-31 2023-12-07 Pfizer Inc. Anti-bmp9 antibodies and methods of use thereof
KR20250122456A (ko) * 2022-11-01 2025-08-13 프로비던스 헬스 앤드 서비시즈 - 오레곤 Fas 리간드에 특이적인 단일클론 항체 및 이의 용도
CN115894675B (zh) * 2023-02-03 2023-11-14 康复大学(筹) 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用
AU2024263454A1 (en) * 2023-04-24 2025-12-11 Elpis Biopharmaceuticals Armored anti-b7h3 car-t cells and uses thereof in cancer therapy
WO2025096542A2 (en) * 2023-10-30 2025-05-08 Immunitas Therapeutics, Inc. Clec2d binding proteins and related methods
WO2026050637A1 (en) * 2024-08-29 2026-03-05 Elpis Biopharmaceuticals Chimeric antigen receptor targeting interleukin- 13 receptor subunit alpha-2 and optionally b7h3 for treating glioblastoma
WO2026064353A1 (en) * 2024-09-17 2026-03-26 The Board Of Regents Of The University Of Texas System Diagnostics and therapeutics targeting slc13a3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US7147854B2 (en) 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US20040001804A1 (en) * 1999-12-30 2004-01-01 Mathew Porunelloor A. LLT uses thereof in immune system modulation
WO2012000994A1 (en) * 2010-06-29 2012-01-05 C.N.R.S. Llt-1 antibodies with new functional properties
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
KR20220007584A (ko) * 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
US20200291120A1 (en) 2020-09-17
JP7875933B2 (ja) 2026-06-18
AU2020222891A1 (en) 2021-08-05
US11827710B2 (en) 2023-11-28
JP2022521705A (ja) 2022-04-12
SG11202108403UA (en) 2021-08-30
CA3129818A1 (en) 2020-08-20
JP7612591B2 (ja) 2025-01-14
US12460007B2 (en) 2025-11-04
AU2020222891B2 (en) 2026-07-16
EP3924385A1 (en) 2021-12-22
NZ778293A (en) 2026-02-27
US20240010733A1 (en) 2024-01-11
WO2020167668A1 (en) 2020-08-20
IL285401A (en) 2021-09-30
JP2025062598A (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
US12460007B2 (en) Antibodies that bind to C-type lectin domain family 2 member D (CLEC2D)
TWI797091B (zh) 利用嵌合抗原受體之癌症治療
EP4245317A1 (en) Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
JP2026062750A (ja) 抗ガレクチン-9抗体及びその使用
TW202019971A (zh) 抗間皮素抗體
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗psgl-1組成物及び方法、ならびにその使用
WO2017149515A1 (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3491016A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
BR112021000397A2 (pt) Fragmentos de ligação fc que compreendem um sítio de ligação a antígeno cd137
KR20210075090A (ko) Gm-csf 길항제를 이용한 면역요법-관련 독성의 치료 방법
TW202210523A (zh) 用於調節骨髓樣細胞發炎表型之抗vsig4組合物及方法以及其用途
JP2024513262A (ja) Nkp46及びcd38を標的とする二重特異性抗体、並びにその使用方法
IL303535A (en) Compositions of guanylyl cyclase C (GCC) antigen binding agents and methods of using them
US10927168B2 (en) Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
JP2025526677A (ja) B7-h3抗原結合性分子
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防
US11130805B2 (en) Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
CN114423452A (zh) 用于调节髓系细胞炎性表型的抗lrrc25组合物和方法及其用途
HK40102796A (en) Cell injury inducing therapeutic drug for use in cancer therapy
JP2024513264A (ja) Nkp46及びgpc3を標的とする二重特異性抗体、並びにその使用方法
HK40120830A (en) Bispecific antibody fusion molecules and methods of use thereof
WO2022225821A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
TW202607042A (zh) 多特異性抗原結合蛋白
HK1258783B (en) Cell injury inducing therapeutic drug for use in cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000